Immuneering Corporation (IMRX) PT Lowered to $15 at Needham, 'to reflect a lower probability of meaningful efficacy as monotherapy'
Tweet Send to a Friend
(Updated - March 15, 2024 7:14 AM EDT)
Needham analyst Ami Fadia lowered the price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst Ami Fadia lowered the price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
